LuÃ-s Pereira de Almeida

List of Publications by Year
in descending order

119 papers	7,296 citations	53794 45 h-index	62596 80 g-index
121 all docs	121 docs citations	121 times ranked	11026 citing authors

#	Article	IF	Citations
1	ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease. Molecular Therapy, 2022, 30, 370-387.	8.2	10
2	Identification of the calpainâ€generated toxic fragment of ataxinâ€3 protein provides new avenues for therapy of Machadoâ€“Joseph disease| Spinocerebellar ataxia type 3. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	4
3	The autophagyâ€enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machadoâ€“Joseph disease. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	15
4	Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity. Movement Disorders, 2022, 37, 405-410.	3.9	8
5	Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo. Biomaterials, 2022, 281, 121366.	11.4	13
6	Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation. Photochemical and Photobiological Sciences, 2022, 21, 1101-1109.	2.9	18
7	Cerebellar morphometric and spectroscopic biomarkers for Machado-Joseph Disease. Acta Neuropathologica Communications, 2022, 10, 37.	5.2	6
8	miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3. Nucleic Acid Therapeutics, 2022, 32, 194-205.	3.6	8
9	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	3.3	25
10	Exogenous loading of extracellular vesicles, virus-like particles, and lentiviral vectors with supercharged proteins. Communications Biology, 2022, 5, 485.	4.4	9
11	SIRT2 Deficiency Exacerbates Hepatic Steatosis via a Putative Role of the ER Stress Pathway. International Journal of Molecular Sciences, 2022, 23, 6790.	4.1	9
12	Differential Temporal Dynamics of Axial and Appendicular Ataxia in <scp>SCA3</scp>. Movement Disorders, 2022, 37, 1850-1860.	3.9	11
13	Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy. Cytokine and Growth Factor Reviews, 2021, 58, 114-133.	7.2	17
14	Neuropeptide Y (NPY) intranasal delivery alleviates Machadoâ€“Joseph disease. Scientific Reports, 2021, 11, 3345.	3.3	11
15	Stress granules, RNA-binding proteins and polyglutamine diseases: too much aggregation?. Cell Death and Disease, 2021, 12, 592.	6.3	74
16	Living Proof of Activity of Extracellular Vesicles in the Central Nervous System. International Journal of Molecular Sciences, 2021, 22, 7294.	4.1	12
17	Polyglutamineâ€Expanded Ataxinâ€3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood. Movement Disorders, 2021, 36, 2675-2681.	3.9	22
18	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (edition)	9.1	1,430

#	Article	IF	Citations
19	The Parkinsonâ€™s-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1. Cell Reports, 2021, 37, 109864.	6.4	20
20	Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening. Pharmaceutics, 2021, 13, 1598.	4.5	10
21	Extracellular Vesicles Physiological Role and the Particular Case of Disease-Spreading Mechanisms in Polyglutamine Diseases. International Journal of Molecular Sciences, 2021, 22, 12288.	4.1	2
22	Autophagy in Spinocerebellar ataxia type 2, a dysregulated pathway, and a target for therapy. Cell Death and Disease, 2021, 12, 1117.	6.3	14
23	Highly Porous Composite Scaffolds Endowed with Antibacterial Activity for Multifunctional Grafts in Bone Repair. Polymers, 2021, 13, 4378.	4.5	9
24	Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain, 2020, 143, 407-429.	7.6	49
25	Mitochondrial and Redox Modifications in Huntington Disease Induced Pluripotent Stem Cells Rescued by CRISPR/Cas9 CAGs Targeting. Frontiers in Cell and Developmental Biology, 2020, 8, 576592.	3.7	24
26	Simple and Fast SEC-Based Protocol to Isolate Human Plasma-Derived Extracellular Vesicles for Transcriptional Research. Molecular Therapy - Methods and Clinical Development, 2020, 18, 723-737.	4.1	24
27	The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples. Acta Neuropathologica Communications, 2020, 8, 152.	5.2	15
28	Mesenchymal Stromal Cellsâ€™ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?. Frontiers in Cellular Neuroscience, 2020, 14, 584277.	3.7	3
29	Gene editing and central nervous system regeneration. , 2020, , 399-433.		0
30	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Molecular Medicine, 2020, 12, e11803.	6.9	73
31	miRNA-31 Improves Cognition and Abolishes Amyloid-Î² Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimerâ€™s Disease. Molecular Therapy - Nucleic Acids, 2020, 19, 1219-1236.	5.1	56
32	Protocol for the Characterization of the Cytosine-Adenine-Guanine Tract and Flanking Polymorphisms in Machado-Joseph Disease. Journal of Molecular Diagnostics, 2020, 22, 782-793.	2.8	1
33	Trehalose alleviates the phenotype of Machadoâ€“Joseph disease mouse models. Journal of Translational Medicine, 2020, 18, 161.	4.4	21
34	Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1073-1078.	3.6	14
35	Machadoâ€“Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. Journal of Neurochemistry, 2019, 148, 8-28.	3.9	92
36	Successes and Hurdles in Stem Cells Application and Production for Brain Transplantation. Frontiers in Neuroscience, 2019, 13, 1194.	2.8	32

#	Article	IF	Citations
37	Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machadoâ€“Joseph disease models. Human Molecular Genetics, 2019, 28, 3691-3703.	2.9	21
38	Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathologica, 2019, 138, 837-858.	7.7	53
39	Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality. Stem Cell Reports, 2019, 12, 878-889.	4.8	68
40	RNA Interference Therapy for Machadoâ€“Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3. Human Gene Therapy, 2019, 30, 841-854.	2.7	18
41	Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machadoâ€“Joseph disease models. Human Molecular Genetics, 2019, 28, 51-63.	2.9	39
42	Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis. Advances in Experimental Medicine and Biology, 2018, 1049, 349-367.	1.6	18
43	Gene Therapies for Polyglutamine Diseases. Advances in Experimental Medicine and Biology, 2018, 1049, 395-438.	1.6	16
44	Stem Cell-Based Therapies for Polyglutamine Diseases. Advances in Experimental Medicine and Biology, 2018, 1049, 439-466.	1.6	12
45	Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 403-413.	2.4	21
46	Generation and characterization of a human iPS cell line from a patient-related control to study disease mechanisms associated with DAND5 p.R152H alteration. Stem Cell Research, 2018, 29, 202-206.	0.7	2
47	Stroma-derived IL-6, G-CSF and Activin-A mediated dedifferentiation of lung carcinoma cells into cancer stem cells. Scientific Reports, 2018, 8, 11573.	3.3	26
48	Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease. Molecular Therapy, 2018, 26, 2131-2151.	8.2	24
49	Loss of hierarchical imprinting regulation at the Praderâ€“Willi/Angelman syndrome locus in human iPSCs. Human Molecular Genetics, 2018, 27, 3999-4011.	2.9	21
50	NEUROPEPTIDE Y RESCUES AGING PHENOTYPE OF HUMAN HUTCHINSON-GILFORD PROGERIA SYNDROME FIBROBLASTS. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR11-1.	0.0	0
51	Non-invasive and allele-specific gene silencing therapy for Machado-Joseph disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR24-4.	0.0	0
52	Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease. Molecular Therapy, 2017, 25, 1038-1055.	8.2	47
53	Unraveling the Role of Ataxin-2 in Metabolism. Trends in Endocrinology and Metabolism, 2017, 28, 309-318.	7.1	23
54	Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia. Annals of Neurology, 2017, 81, 407-418.	5.3	19

#	Article	IF	Citations
55	Control of Huntingtonâ€™s Disease-Associated Phenotypes by the Striatum-Enriched Transcription Factor Foxp2. Cell Reports, 2017, 21, 2688-2695.	6.4	22
56	Generation of human iPSC line from a patient with laterality defects and associated congenital heart anomalies carrying a DAND5 missense alteration. Stem Cell Research, 2017, 25, 152-156.	0.7	11
57	Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. Journal of Controlled Release, 2017, 262, 247-258.	9.9	298
58	Proteolytic Cleavage of Polyglutamine Disease-Causing Proteins: Revisiting the Toxic Fragment Hypothesis. Current Pharmaceutical Design, 2017, 23, 753-775.	1.9	28
59	Caloric restriction stimulates autophagy in rat cortical neurons through neuropeptide Y and ghrelin receptors activation. Aging, 2016, 8, 1470-1484.	3.1	50
60	Motor Dysfunctions and Neuropathology in Mouse Models of Spinocerebellar Ataxia Type 2: A Comprehensive Review. Frontiers in Neuroscience, 2016, 10, 572.	2.8	21
61	Caloric restriction blocks neuropathology and motor deficits in Machadoâ€“Joseph disease mouse models through SIRT1 pathway. Nature Communications, 2016, 7, 11445.	12.8	86
62	Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. Journal of Controlled Release, 2016, 241, 94-109.	9.9	148
63	Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases. Neurobiology of Disease, 2016, 95, 210-224.	4.4	98
64	Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment. Scientific Reports, 2016, 6, 28220.	3.3	68
65	Adenosine A2A Receptors in the Amygdala Control Synaptic Plasticity and Contextual Fear Memory. Neuropsychopharmacology, 2016, 41, 2862-2871.	5.4	75
66	Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models. Journal of Cell Biology, 2016, 212, 465-480.	5.2	35
67	Safety profile of the intravenous administration of brain-targeted stable nucleic acid lipid particles. Data in Brief, 2016, 6, 700-705.	1.0	11
68	Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. Biomaterials, 2016, 82, 124-137.	11.4	86
69	Gephyrin Cleavage in In Vitro Brain Ischemia Decreases GABAA Receptor Clustering and Contributes to Neuronal Death. Molecular Neurobiology, 2016, 53, 3513-3527.	4.0	41
70	487. Non-Viral Silencing of Machado-Joseph Disease Through the Systemic Route. Molecular Therapy, 2015, 23, S193-S194.	8.2	0
71	Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machadoâ€“Joseph disease. Human Molecular Genetics, 2015, 24, 5451-5463.	2.9	43
72	MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. Journal of Controlled Release, 2015, 207, 31-39.	9.9	167

#	Article	IF	Citations
73	Neuropeptide Y stimulates autophagy in hypothalamic neurons. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1642-E1651.	7.1	60
74	Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machadoâ€“Joseph disease. Brain, 2015, 138, 3537-3554.	7.6	32
75	Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain, 2015, 138, 320-335.	7.6	78
76	Fluoxetine Induces Proliferation and Inhibits Differentiation of Hypothalamic Neuroprogenitor Cells In Vitro. PLoS ONE, 2014, 9, e88917.	2.5	11
77	IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice. Molecular Neurobiology, 2014, 49, 1126-1142.	4.0	60
78	Let-7 Coordinately Suppresses Components of the Amino Acid Sensing Pathway to Repress mTORC1 and Induce Autophagy. Cell Metabolism, 2014, 20, 626-638.	16.2	67
79	Role of hypothalamic neurogenesis in feeding regulation. Trends in Endocrinology and Metabolism, 2014, 25, 80-88.	7.1	88
80	Early miR-155 upregulation contributes to neuroinflammation in Alzheimer's disease triple transgenic mouse model. Human Molecular Genetics, 2014, 23, 6286-6301.	2.9	133
81	Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machadoâ€“Joseph disease. Human Molecular Genetics, 2014, 23, 4932-4944.	2.9	46
82	RNA Interference Mitigates Motor and Neuropathological Deficits in a Cerebellar Mouse Model of Machado-Joseph Disease. PLoS ONE, 2014, 9, e100086.	2.5	33
83	Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment. Molecular Therapy - Nucleic Acids, 2013, 2, e100.	5.1	83
84	MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Human Molecular Genetics, 2013, 22, 904-918.	2.9	79
85	Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machadoâ€“Joseph disease. Brain, 2013, 136, 2173-2188.	7.6	86
86	Caffeine and adenosine A_{2A} receptor inactivation decrease striatal neuropathology in a lentiviralâ€based model of Machadoâ€“Joseph disease. Annals of Neurology, 2013, 73, 655-666.	5.3	77
87	Overexpression of Mutant Ataxin-3 in Mouse Cerebellum Induces Ataxia and Cerebellar Neuropathology. Cerebellum, 2013, 12, 441-455.	2.5	24
88	Silencing Mutant Ataxin-3 Rescues Motor Deficits and Neuropathology in Machado-Joseph Disease Transgenic Mice. PLoS ONE, 2013, 8, e52396.	2.5	104
89	PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. Human Molecular Genetics, 2012, 21, 5118-5130.	2.9	24
90	Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain, 2012, 135, 2428-2439.	7.6	98

#	Article	IF	Citations
91	miRâ€155 modulates microgliaâ€mediated immune response by downâ€regulating SOCSâ€1 and promoting cytokine and nitric oxide production. Immunology, 2012, 135, 73-88.	4.4	283
92	Moderate Long-Term Modulation of Neuropeptide Y in Hypothalamic Arcuate Nucleus Induces Energy Balance Alterations in Adult Rats. PLoS ONE, 2011, 6, e22333.	2.5	44
93	Beclin-1 and autophagy: potential for new therapeutics in neurodegeneration. Neurodegenerative Disease Management, 2011, 1, 349-351.	2.2	0
94	Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials. Current Pharmaceutical Design, 2011, 17, 3434-3445.	1.9	20
95	Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machadoâ€"Joseph disease. Brain, 2011, 134, 1400-1415.	7.6	171
96	Cleavage of the Vesicular GABA Transporter under Excitotoxic Conditions Is Followed by Accumulation of the Truncated Transporter in Nonsynaptic Sites. Journal of Neuroscience, 2011, 31, 4622-4635.	3.6	42
97	Proliferative Hypothalamic Neurospheres Express NPY, AGRP, POMC, CART and Orexin-A and Differentiate to Functional Neurons. PLoS ONE, 2011, 6, e19745.	2.5	31
98	Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. Journal of Controlled Release, 2010, 142, 392-403.	9.9	48
99	Characterization of common and rare human papillomaviruses in Portuguese women by the polymerase chain reaction, restriction fragment length polymorphism and sequencing. Journal of Medical Virology, 2010, 82, 1024-1032.	5.0	11
100	Silencing ataxin-3 mitigates degeneration in a rat model of Machadoâ€"Joseph disease: no role for wild-type ataxin-3?. Human Molecular Genetics, 2010, 19, 2380-2394.	2.9	96
101	Tf-lipoplexes for neuronal siRNA delivery: A promising system to mediate gene silencing in the CNS. Journal of Controlled Release, 2008, 132, 113-123.	9.9	75
102	Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. Journal of Clinical Virology, 2008, 42, 13-21.	3.1	47
103	Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Human Molecular Genetics, 2008, 17, 2071-2083.	2.9	78
104	Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in a Rat Model of Machado-Joseph Disease. PLoS ONE, 2008, 3, e3341.	2.5	141
105	Surfactants as Microbicides and Contraceptive Agents: A Systematic In Vitro Study. PLoS ONE, 2008, 3, e2913.	2.5	52
106	siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. Journal of Gene Medicine, 2007, 9, 170-183.	2.8	89
107	Polyglutamine Expansion Diseases â€" the Case of Machado-Joseph Disease. , 2007, , 391-426.		0
108	Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Therapy, 2005, 12, 1242-1252.	4.5	62

#	Article	IF	Citations
109	Molecular Targets and Therapeutic Strategies in Huntingtons Disease. CNS and Neurological Disorders, 2005, 4, 361-381.	4.3	19
110	Liposomal and Viral Vectors for Gene Therapy of the Central Nervous System. CNS and Neurological Disorders, 2005, 4, 453-465.	4.3	18
111	Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology, 2004, 185, 26-35.	4.1	54
112	Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. Journal of Controlled Release, 2003, 87, 107-115.	9.9	47
113	Dose-Dependent Neuroprotective Effect of Ciliary Neurotrophic Factor Delivered via Tetracycline-Regulated Lentiviral Vectors in the Quinolinic Acid Rat Model of Huntington's Disease. Human Gene Therapy, 2002, 13, 1981-1990.	2.7	109
114	Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length. Journal of Neuroscience, 2002, 22, 3473-3483.	3.6	184
115	Neuroprotective Effect of a CNTF-Expressing Lentiviral Vector in the Quinolinic Acid Rat Model of Huntington's Disease. Neurobiology of Disease, 2001, 8, 433-446.	4.4	150
116	Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. European Journal of Neuroscience, 2001, 14, 1753-1761.	2.6	44
117	Self-Inactivating Lentiviral Vectors with Enhanced Transgene Expression as Potential Gene Transfer System in Parkinson's Disease. Human Gene Therapy, 2000, 11, 179-190.	2.7	276
118	Modeling Dissolution of Sparingly Soluble Multisized Powders. Journal of Pharmaceutical Sciences, 1997, 86, 726-732.	3.3	38
119	Testing the applicability of classical diffusional models to polydisperse systems. International Journal of Pharmaceutics, 1996, 139, 169-176.	5.2	7